Strona główna・Stock List・Galectin Therapeutics Inc

Galectin Therapeutics Inc

Closed

SectorHealthcare

2.97 -1

Buy Sell

Overview

Share price change

24h

Current

Min

2.94

Max

3.16

Key metrics
By Trading Economics
Income	454K -5M
EPS	-0.08
Employees	9
EBITDA	474K -3M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+270.37% upside

Dividends
By Acuity
Next Earnings	12 sie 2026

Market Stats
By TradingEconomics
Market Cap	77M 223M
Previous open	3.97
Previous close	2.97

News Sentiment

By Acuity

25%

75%

73 / 340 Ranking in Healthcare

Galectin Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

3 sie 2026, 19:46 UTC

Galectin Therapeutics Inc is higher today, continuing an upward trend since Friday's close, despite pulling back from a session high. No specific news was identified.

31 lip 2026, 21:51 UTC

Galectin Therapeutics Inc is lower in after-market trading, influenced by broader market trends. The asset has faced three consecutive sessions of declines.

30 lip 2026, 20:10 UTC

Galectin Therapeutics Inc is lower today, breaking a trend of higher daily closes. Increased market volume accompanies the decline amid broader market volatility.

29 lip 2026, 18:58 UTC

Galectin Therapeutics Inc shares are higher today, continuing an upward trend since Tuesday's close. The stock remains below its 20-day moving average.

28 lip 2026, 17:46 UTC

Galectin Therapeutics Inc shares are lower today, continuing a decline since Monday's close, amid broader market caution following significant drops in Asian indices.

27 lip 2026, 16:32 UTC

Galectin Therapeutics Inc shares are lower today, reflecting a notable decline since Friday. The stock has seen unusually high trading volume amid broader market sentiment.

24 lip 2026, 20:02 UTC

Galectin Therapeutics Inc is lower today, marking its ninth consecutive session of declines. The stock remains below its 20-day moving average.

22 lip 2026, 19:01 UTC

Galectin Therapeutics Inc. shares are trading lower, following a peak earlier in the session. High trading volume indicates increased investor activity.

21 lip 2026, 17:16 UTC

Galectin Therapeutics Inc. shares are lower today, continuing a five-session decline and trading significantly below the 20-day moving average. No specific news was identified.

20 lip 2026, 20:06 UTC

Galectin Therapeutics Inc shares are lower today, continuing a trend of five consecutive daily declines amid broader market volatility linked to geopolitical tensions.

Peer Comparison

Price change

Galectin Therapeutics Inc Forecast

Price Target

By TipRanks

270.37% upside

12 Months Forecast

Average 11 USD 270.37%

High 11 USD

Low 11 USD

Based on 1 Wall Street analysts offering 12 month price targets forGalectin Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

1 ratings

Buy

Hold

Sell

Based on 1 analysts giving stock ratings to Galectin Therapeutics Inc - Dist in the past 3 months.

Sentiment

By Acuity

73 / 340 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Galectin Therapeutics Inc

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.